1. Market Research
  2. > Cancer
Customer Support

Talk to Ahmad

+1 718 618 4302

Top Countries

Publishers

  • All
    • Firstword Pharma
4 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2018]

  • $ 9000
  • April 2018
  • 1 pages

What are the key opportunities for CAR-T in other disease areas (multiple myeloma, lymphoma and chronic lymphocytic leukaemia [CLL]) and which ones are KOLs most excited about?

  • Immunotherapy
  • Lymphoma
  • Therapy
  • United States

CAR-T Therapy in Haematological Malignancy: Update Bulletin #2

  • $ 1151
  • December 2017
  • 1 pages

lymphoma (DLBCL) respectively.

  • Cancer
  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • United States

CAR-T Disease Outlook [2017]

  • $ 8658
  • June 2017
  • 1 pages

I see them being used for lymphoma, ALL, and in multiple myeloma, we' ll have to see. ”US Key Opinion Leader “The responses for ALL are unprecedented.

  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy

Chronic Lymphocytic Leukaemia: KOL Insight 2017

  • $ 8658
  • August 2017
  • 1 pages

Chronic Lymphocytic Leukaemia: KOL Insight 2017 ##.

  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • United States


View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on